Prolonged opioid antagonism with naloxone in chronic renal failure

Pharmacotherapy

Volumn 19, Issue 7, 1999, Pages 897-901

  Hanes, Scott D ^a   Franklin, Michael ^b   Kuhl, David A ^a   Headley, A Stacey ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; OPIATE;

AGED; ARTICLE; CASE REPORT; CHRONIC KIDNEY FAILURE; CONTINUOUS INFUSION; DRUG INTOXICATION; DRUG METABOLISM; GERIATRIC PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PATIENT CONTROLLED ANALGESIA; POSTOPERATIVE ANALGESIA; POSTOPERATIVE PAIN; RESPIRATION DEPRESSION; TOTAL HIP PROSTHESIS;

AGED; ANALGESICS, OPIOID; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MORPHINE; NALOXONE; NARCOTIC ANTAGONISTS; RESPIRATORY INSUFFICIENCY; TIME FACTORS;

EID: 0032834597     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.10.897.31557     Document Type: Article

References (22)

1. Glare PA, Walsh TD. Clinical pharmacokinetics of morphine. Ther Drug Monit 1991;13:1-23.
2. Gong QL, Hedner T, Hedner J, Björkman R, Nordberg G. Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide. Eur J Pharmacol 1991;193:47-56.
3. Hanna MH, D'Costa F, Peat SJ, et al. Morphine-6-glucuronide disposition in renal impairment. Br J Anaesth 1993;70:511-14.
4. Osbourne R, Joel S, Grebenik K, Trew D, Slevin M. The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther 1993;54:158-67.
5. Portenoy RK, Foley KM, Stulman J, et al. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain 1991;47:13-19.
6. Goldfrank L, Weisman RS, ErricK JK, Lo MW. A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med 1986;15:566-70.
7. Ngai SH, Berkowitz BA, Yang JC, Hempstead J, Spector S. Pharmacokinetics of naloxone in rat and man: basis for its potency and short duration of action. Anesthesiology 1976;44:398-401.
8. Fishman J, Roffwarg H, Hellman L. Disposition of naloxone-7.8-H3 in normal and narcotic-dependent men. J Pharmacol Exp Ther 1973;187:575-80.
9. Kaufman RD, Gabathuler ML, Bellville JW. Potency, duration of action and pA2 in man of intravenous naloxone measure by reversal of morphine-depressed respiration. J Pharmacol Exp Ther 1981;219:156-62.
10. Handal KA, Schauben JL, Salamone FR. Naloxone. Ann Emerg Med 1983;12:438-45.
11. Franklin M, Odontiadis J. Determination of naloxone in human plasma by high-performance liquid chromatography with coulometric detection. J Chromatogr B Biomed Appl 1996;679:199-203.
12. Wahlström A, Persson K, Rane A. Metabolic interaction between morphine and naloxone in human liver. Drug Metab Dispos 1989;17:218-20.
13. Garrett ER, Shyu WC, Ulubelen A. Pharmacokinetics of morphine and its surrogates. VII. Naloxone and naloxone conjugate pharmacokinetics in dogs as a function of dose and as affected by simultaneously administered morphine. J Pharm Sci 1986;75:1127-36.
14. Asali LA, Brown KF. Naloxone protein binding in adult and foetal plasma. Eur J Clin Pharmacol 1984;27:459-63.
15. Vasson MP, Baguet JC, Arveiller MB, Bargnoux PJ, Giroud AP, Raichvarg D. Serum and urinary alpha-1 acid glycoprotein in chronic renal failure. Nephron 1993;65:299-303.
16. Touchelte MA, Slaughter RL. The effects of renal failure on hepatic drug clearance. Ann Pharmacother 1991;25:1214-24.
17. Matzke GR, Frye RF, Alexander ACM, et al. The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene. J Clin Pharmacol 1996;36:144-51.
18. Lehmann CR, Heiroimus JD, Collins CB, et al. Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis. Clin Pharmacol Ther 1985;37:284-9.
19. Anders MW. Metabolism of drugs by the kidney. Kidney Int 1980;18:636-47.
20. Fujimoto JM, Roerig S, Wang RIH, Chatterjie N, Inturrisi CE. Narcotic antagonistic activity of several metabolites of naloxone and naltrexone tested in morphine dependent mice. Proc Soc Exp Biol Med 1975;148:443-8.
21. Weinstein SH, Pfeffer M, Schor JM, Indindoli L, Mintz M. Metabolites of naloxone in human urine. J Pharm Sci 1971;60:1567-8.
22. Covington EC, Gonsalves-Ebrahim L, Currie KO, Shepard KV, Pippenger CE. Severe respiratory depression from patient controlled analgesia in renal failure. Psychosomatics 1989;30:226-8.